Orphan Drug Designation is a critical regulatory milestone that can lead to market exclusivity, tax benefits, and assistance from the European Medicines Agency in the drug development process. This designation is likely to positively impact Moleculin's stock price in the short term due to the potential for accelerated development and approval of their treatment in Europe, along with the financial incentives associated with the designation.